



*Roche Venture Fund  
invests to develop  
commercially successful  
innovative life science  
companies*

**About Us**

We are the corporate venture fund of Roche, a global leader in bringing medicines and *in vitro* diagnostics to the benefit of patients.

We make investments in life science companies aiming to create value by fostering innovation, guiding successful businesses and generating financial return to Roche.

Our commitment to investments is not just about funding - we provide our team's expertise and the promise of long term vision to drive our shared success together.



Roche Venture Fund  
F. Hoffmann-La Roche Ltd  
4070 Basel, Switzerland

[www.venturefund.roche.com](http://www.venturefund.roche.com)

© 2013

**Roche Venture Fund**  
*Connecting Innovation to Value*



## A Culture of *Innovation*

Our dedicated team is self contained with a mandate for independent decision making on new and existing investments.

We invest in private companies with innovative medicines, diagnostics and technologies. In select cases, we will invest in companies alongside research and development collaborations with Roche or Genentech.

We share Roche's culture of innovation. We are global, forward looking and willing to take risks on innovations with high potential reward.

We are immersed in entrepreneurialism. In addition to our portfolio companies, we are active in start-up communities and maintain a strong network of entrepreneurs and fellow investors.

Our knowledge is strengthened by our access to the expertise of Roche and Genentech. We benefit from the insight of an organization that has brought first-in-class therapeutics, diagnostics and research tools to patients and health care providers.



## Long-term *Commitment*

Success needs time, dedication and experience. An investment has to be more than a funding round: an investment means a proactive and long-term engagement.

We are hands on. We spend time on the ground with our companies, taking board seats where appropriate.

We are an evergreen fund and have reserves if and when follow-on financing rounds are needed.

Our current portfolio includes more than 30 companies.

## *Innovation*

## *Commitment*

## *Success*

### **Fast Facts**

- A CHF 500M evergreen fund
- Invest in life science companies in both pharmaceuticals and diagnostics
- Focus on financial returns
- Reports into the Roche Group finance organization
- Active involvement in an investment portfolio of over 30 companies
- Team located in Basel, Switzerland and South San Francisco, USA
- For more detailed information: [www.venturefund.roche.com](http://www.venturefund.roche.com)

## Defining *Success*

We seek to add value to our companies and create highly valuable business enterprises.

Our objectives are exits via initial public offering (IPO) or company acquisition.

To date, we have had over 20 exits on the public markets and 12 of our portfolio companies have been acquired.



### **A rewarding investment: Envoy Therapeutics**

Envoy was a spin-out from The Rockefeller University. It captured our interest with an intriguing technology called bacTRAP.

The promise to break new ground in drug discovery led us to invest \$2M in an \$8M Series A round in 2009.

Envoy developed rapidly and within 3 years, secured 2 pharma partners with an expanding preclinical pipeline and short term projections to reach the clinic.

By 2012, Envoy was acquired by Takeda for \$140M in upfront and milestone payments.